IDEAS home Printed from https://ideas.repec.org/p/wbk/wbrwps/2811.html
   My bibliography  Save this paper

The epidemiological impact of an HIV/AIDS vaccine in developing countries

Author

Listed:
  • Stover, John
  • Garnett, Geoff P.
  • Seitz, Steve
  • Forsythe, Steven

Abstract

Many people see an effective preventive AIDS vaccine as the best solution to the HIV/AIDS pandemic. Ten years ago many scientists had hoped that a vaccine would be available by now. Most scientists are still optimistic that vaccines will be developed and many candidates are being tested. Strategies to implement HIV/AIDS vaccination need to be developed to be ready when vaccines do become available. The nature of those programs will depend on the characteristics of each vaccine. How much does it cost? How effective is it? How long does protection last? The answers to these and other questions will help determine issues such as: What will be the impact of the vaccine on the epidemic? Who should be vaccinated? Will an AIDS vaccine be more cost-effective than other prevention measures? Will other measures still be necessary? What will happen to the epidemic if vaccination leads to riskier behavior? How much funding will be needed? The authors use two computer simulation models to investigate the effects of various vaccine characteristics and implementation strategies on the impact and cost-effectiveness of vaccines in different contexts. A simulation model is applied to data from rural Zimbabwe and the iwgAIDS model is applied to Kampala (Uganda) and Thailand. The models are used to investigate the effects of efficacy, duration, cost, and type of protection on impact and cost-effectiveness. The models also show the merits of targeting public subsidies to various population groups: all adults, teenagers, high-risk groups, and women of reproductive age. The impact of vaccines on the epidemic is compared with the impact of other prevention interventions such as condom use and behavior change. Finally, the models are used to explore the extent with which behavioral reversals may erode the positive benefits of the vaccine. A highly effective, long-lasting, inexpensive vaccine would be ideal and could make a major contribution in controlling the HIV/AIDS pandemic. But vaccines that do not attain this ideal can still be useful. A vaccine with 50 percent efficacy and 10 years duration supplied to 65 percent of all adults could reduce HIV incidence by 25 to 60 percent, depending on the context and stage of the epidemic. Better efficacy and longer duration would provide even more impact. Programs focused on teenagers or high-risk populations have less overall impact but would provide significant benefits at much less cost than those reaching all adults. Behavioral reversals could erode much of the benefits of vaccination programs so it will be important to combine vaccination with continued messages about the importance of safe behaviors. The cost of the vaccines is not known at this time. At a cost of $10 or $20 per person vaccinated, the cost per infection averted would be as low or lower than other prevention interventions. Higher costs for the vaccines and the need for many booster shots could reduce the cost-effectiveness significantly.

Suggested Citation

  • Stover, John & Garnett, Geoff P. & Seitz, Steve & Forsythe, Steven, 2002. "The epidemiological impact of an HIV/AIDS vaccine in developing countries," Policy Research Working Paper Series 2811, The World Bank.
  • Handle: RePEc:wbk:wbrwps:2811
    as

    Download full text from publisher

    File URL: http://www-wds.worldbank.org/external/default/WDSContentServer/WDSP/IB/2002/04/12/000094946_02040304241296/Rendered/PDF/multi0page.pdf
    Download Restriction: no
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Desmond, Christopher & Greener, Robert, 2003. "The strategic use and potential demand for an HIV vaccine in Southern Africa," Policy Research Working Paper Series 2977, The World Bank.
    2. Dutilh Novaes, Hillegonda Maria & Luna, Expedito J.A. & Goldbaum, Moises & Kilsztajn, Samuel & Rossbach, Anaclaudia & de la Roca Carvalheiro, Jose, 2002. "The potential demand for an HIV/AIDS vaccine in Brazil," Policy Research Working Paper Series 2940, The World Bank.
    3. Suraratdecha, Chutima & Ainsworth, Martha & Tangcharoensathien, Viroj & Whittington, Dale, 2005. "The private demand for an AIDS vaccine in Thailand," Health Policy, Elsevier, vol. 71(3), pages 271-287, March.
    4. Nagelkerke, Nico J.D. & De Vlas, Sake J., 2003. "The epidemiological impact of an HIV vaccine on the HIV/AIDS epidemic in Southern India," Policy Research Working Paper Series 2978, The World Bank.
    5. Mead Over & Peter Heywood & Julian Gold & Indrani Gupta & Subhash Hira & Elliot Marseille, 2004. "HIV/AIDS Treatment and Prevention in India : Modeling the Cost and Consequences," World Bank Publications - Books, The World Bank Group, number 14916.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wbk:wbrwps:2811. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Roula I. Yazigi (email available below). General contact details of provider: https://edirc.repec.org/data/dvewbus.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.